biovature
Develops 4D-Fibroprinting technology combining 3D bioprinting with in situ fiber spinning for artificial living tissues with personalized shapes, cells, and natural fibrillar/vascular structures.
- CEO / Founder
- Alla Synytska
- Team Size
- 1-10
- Stage
- Active
Technology & Products
Key Products
4D-Fibroprinting technology for artificial living tissues and organs, including potential applications for skin, natural breast implants, and other organs from cultured patient cells.
Technological Advantage
Proprietary method allows ultrafast and effective production of artificial living tissues, with applications in personalized medicine and orthopedic implants; technology is protected by patents.
Differentiation
Value Proposition
Enables production of complex artificial tissues with natural fibrous structures for applications like muscle tissue engineering, orthopedic implants, and fiber-reinforced composites, potentially accelerating regenerative medicine.
How They Differentiate
Focuses on 4D-Fibroprinting with in situ fiber spinning for natural fibrous structures, unlike competitors using standard extrusion or inkjet bioprinting; targets personalized tissue shapes and vascularization.
Market & Competition
Target Customers
Research institutions, biomedical companies, tissue engineering labs
Industry Verticals
Medical; Biotechnology
Competitors
CELLINK (BICO Group), SunP Biotech, Poietis, REGENHU
Growth & Milestones
Growth Metrics
Biovature is mentioned as a supporting SME partner in a University of Bayreuth project 'Bi3DAN,' which received approximately €1.3 million in EU ERDF funding for additive manufacturing research involving 3D bioprinting, xolography, electrospinning, and nanohydrogels.
Major Milestones
Founded in 2022; Development of 4D-Fibroprinting technology; Collaborations with University of Bayreuth and Fraunhofer IPA